Interim Analysis of CONFIDENCE: A Prospective Observational Study With Acute Treatment of Rimegepant ODT on Consistency, Satisfaction, and Tolerability of Treatment in the Real World
Abraham L, Urani A, Lambru G, Lipton RB, Goadsby PJ,
Pozo-Rosich P, Schwedt TJ, Galabova B, Dai F, Hygge Blakeman K
AHS 2025
- 美国头痛学会年会 2025
| 偏头痛
Long-term Safety and Discontinuation for Rimegepant versus Triptans: A Matching-Adjusted Indirect Comparison
Powell L, de Brún C, Rogula B, Jenkins A, Atkinson J, Abraham L
AHS 2025
- 美国头痛学会年会 2025
| 偏头痛
A Retrospective Cohort Study Comparing Persistence Between Rimegepant and Lasmiditan for the Acute Treatment of Migraine in the United States
Jenkins A, Hygge Blakeman K, Turko A, Dai F, Dagenais S, Henriksen C, Abraham L
AHS 2025
- 美国头痛学会年会 2025
| 偏头痛
Shifting the Narrative: Trends in Stigmatizing Language and Sentiment Towards Migraine Treatments on Social Media
Monteith TS, Verduzco-Gutierrez M, Ehrlich A, Moran H, Riggins N, Starling AJ, Fajardo M, Sweeney S
AHS 2025
- 美国头痛学会年会 2025
| 偏头痛
A Phase 4 Randomized Double-blind Placebo-Controlled Study of Rimegepant for Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
Ashina M, McAllister P, Ramirez LM, Nalpas C, Thiry A, Abraham L, Fountaine R, Fullerton T
AHS 2025
- 美国头痛学会年会 2025
| 偏头痛
Real-world Diagnostic Pathway and Prescribing Patterns in Patients Newly Diagnosed with Migraine in the United States from 2018-2021
Martin V, Patel A, Dagenais S, Corman S, Tellor K, Fajardo M, Turko A, Agarwal E, Cohen F
AHS 2025
- 美国头痛学会年会 2025
| 偏头痛
